Four-time PGA TOUR winner Tim Herron is teaming up with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), Damon Adamany, MD, of The CORE Institute and the Facts on Hand campaign to educate adults about one of the more common hand conditions. The campaign is raising awareness of Dupuytren’s Contracture, a progressive, potentially disfiguring hand condition affecting a layer of tissue underneath the palms that can cause one or more fingers to move into a bent position so they cannot be straightened.
Dupuytren’s Contracture, sometimes referred to as “Viking Disease,” can make everyday tasks difficult, such as grabbing an object at home, or in Tim Herron’s case, a nine iron from his golf bag. Many people live with the disease without being diagnosed because they mistakenly assume they have arthritis or another hand condition. And because Dupuytren’s Contracture may progress slowly, people may not pay attention to it until they can no longer straighten their fingers, complicating everyday activities.
To view the multimedia release go to:
Nationally-recognized and long-standing sports announcer Jerry Punch, M.D., is teaming up with Men’s Health Network and Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), to launch “Ask About the Curve,” a new educational campaign designed to raise awareness of Peyronie’s disease. Peyronie’s disease is a little-known men’s health condition that can occur during midlife or later. And, while the disease is physical in nature, the impact may also be psychological and could possibly hold men back from talking about it.
Peyronie’s disease, or “PD,” is a condition that can cause curvature of the penis that could be painful during arousal and intimacy. It can affect as many as one in 10 men worldwide, but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help. Together with Endo and Men’s Health Network, Dr. Punch is encouraging men who think they might have PD to face their challenge head on by starting the conversation with their doctor.
“As a sports commentator, I’ve witnessed thousands of men on the court, on the field and on the racetrack in their physical prime – cool, confident and thriving in the face of challenge. But, as a licensed physician, I’ve seen how this bravado can turn to embarrassment – even isolation – when that challenge becomes personal or intimate,” said Dr. Punch. “Often, men feel too awkward to talk about issues like Peyronie’s disease, even with a doctor. And while it may seem tough, it’s important that any man with PD see a doctor, and ask about the curve. Starting the conversation is the first step to getting help.”
To view the multimedia release go to:
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/